Home Newsfeeds Bealarus Says It Downed Ukrainian S-300 Missile In Brest Region

Bealarus Says It Downed Ukrainian S-300 Missile In Brest Region

-Reuters

byBill Haddad

December 29, 2022

1 minute read

-Reuters

News

Red Cat Integrates Advanced AI Capabilities Into Next-Generation Drone System For The U.S. Army’s Short Range Reconnaissance Program

By Benzinga Newsdesk

January 23, 9:23 AM

Red Cat Holdings, Inc. (NASDAQ:RCAT) ("Red Cat" or the "Company"), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, announces it will integrate

RCAT

These Analysts Cut Their Forecasts On J.B. Hunt Following Downbeat Earnings

By Avi Kapoor

April 17, 7:33 AM

J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT) reported downbeat first-quarter 2024 results on Tuesday.

JBHT

Aurora Shares Plunge On Q4 Earnings Report But This Analyst Sees Better Days Ahead, Here’s Why

By Jelena Martinovic

September 21, 10:40 AM

Aurora Cannabis Inc. (NASDAQ: ACB) reported its financial and operational results for the fourth quarter and fiscal year ending June 30, 2022

ACB

Compass Therapeutics Receives FDA Fast Track Designation For The Investigation Of CTX-009 In Combination With Paclitaxel For The Treatment Of Patients With Metastatic Or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

By Benzinga Newsdesk

April 25, 8:01 AM

CTX-009, the Company's bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 studyTop-line data

CMPX

Bealarus Says It Downed Ukrainian S-300 Missile In Brest Region

Related Posts

Red Cat Integrates Advanced AI Capabilities Into Next-Generation Drone System For The U.S. Army’s Short Range Reconnaissance Program

These Analysts Cut Their Forecasts On J.B. Hunt Following Downbeat Earnings

Aurora Shares Plunge On Q4 Earnings Report But This Analyst Sees Better Days Ahead, Here’s Why

Compass Therapeutics Receives FDA Fast Track Designation For The Investigation Of CTX-009 In Combination With Paclitaxel For The Treatment Of Patients With Metastatic Or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated